Sensei Biotherapeutics, Inc. (FTH) - What Are Researchers Saying About This Stock?

Sensei Biotherapeutics logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Analysts give Sensei Biotherapeutics a “Moderate Buy” consensus: Of 17 covering firms, 13 rate it buy and two strong buy, while one rates it hold and one sell. The average 12-month price target is $56.58; Citigroup recently raised its target to $60.
  • FTH opened at $9.28, versus a 52-week range of $7.45–$42.14, and had a market capitalization of about $239.8 million.
  • The company reported quarterly EPS of -$0.79, missing analysts’ consensus estimate of -$0.66; analysts forecast a loss of $14.01 per share for the current year.
  • MarketBeat previews top five stocks to own in December.

Sensei Biotherapeutics, Inc. (NASDAQ:FTH - Get Free Report) has been assigned an average rating of "Moderate Buy" from the seventeen ratings firms that are currently covering the company, Marketbeat reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating, thirteen have given a buy rating and two have issued a strong buy rating on the company. The average twelve-month price objective among brokerages that have covered the stock in the last year is $56.58.

FTH has been the subject of a number of recent analyst reports. Citigroup raised their price objective on shares of Sensei Biotherapeutics from $55.00 to $60.00 and gave the stock a "buy" rating in a research note on Tuesday, November 10th. Citizens Jmp started coverage on shares of Sensei Biotherapeutics in a research report on Monday, July 20th. They set an "outperform" rating and a $51.00 price objective on the stock. Weiss Ratings reissued a "sell (d-)" rating on shares of Sensei Biotherapeutics in a research note on Monday, September 14th. William Blair initiated coverage on shares of Sensei Biotherapeutics in a research note on Friday, October 16th. They set an "outperform" rating on the stock. Finally, Raymond James Financial began coverage on Sensei Biotherapeutics in a report on Friday, July 31st. They issued an "outperform" rating and a $56.00 target price for the company.

Read Our Latest Research Report on FTH

Sensei Biotherapeutics Stock Performance

Shares of FTH opened at $9.28 on Friday. Sensei Biotherapeutics has a one year low of $7.45 and a one year high of $42.14. The stock has a 50-day moving average price of $24.45. The firm has a market capitalization of $239.80 million, a PE ratio of -0.07 and a beta of -0.15.

Sensei Biotherapeutics (NASDAQ:FTH - Get Free Report) last released its earnings results on Tuesday, November 3rd. The company reported ($0.79) earnings per share for the quarter, missing the consensus estimate of ($0.66) by ($0.13). On average, sell-side analysts forecast that Sensei Biotherapeutics will post -14.01 EPS for the current year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of FTH. State of Wyoming purchased a new stake in Sensei Biotherapeutics in the 3rd quarter worth about $25,000. China Universal Asset Management Co. Ltd. boosted its position in Sensei Biotherapeutics by 48.9% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 5,360 shares of the company's stock worth $150,000 after acquiring an additional 1,760 shares during the period. Citadel Advisors LLC purchased a new position in Sensei Biotherapeutics during the 2nd quarter valued at about $307,000. Jump Financial LLC purchased a new position in Sensei Biotherapeutics during the 3rd quarter valued at about $694,000. Finally, Renaissance Technologies LLC grew its stake in Sensei Biotherapeutics by 178.2% during the 1st quarter. Renaissance Technologies LLC now owns 32,041 shares of the company's stock valued at $1,010,000 after acquiring an additional 20,525 shares in the last quarter. 10.50% of the stock is owned by institutional investors and hedge funds.

Sensei Biotherapeutics Company Profile

(Get Free Report)

Sensei Biotherapeutics is a biotechnology company focused on developing immunotherapies for cancer. Its research centers on treatments intended to address immune suppression in the tumor microenvironment and help the body's immune system recognize and attack cancer cells. The company's publicly disclosed research programs have included SNS-101, an antibody designed to target VISTA, an immune checkpoint protein, and SNS-301, an investigational cancer immunotherapy. These programs were in development rather than marketed products.

See Also

Analyst Recommendations for Sensei Biotherapeutics (NASDAQ:FTH)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Sensei Biotherapeutics Right Now?

Before you consider Sensei Biotherapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sensei Biotherapeutics wasn't on the list.

While Sensei Biotherapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines